CMOs to keep prospering from approvals of COVID-19 products and cell therapies

The US Food and Drug Administration’s (FDA) increasing approvals and Emergency Use Authorizations (EUAs) of COVID-19 vaccines and drugs, as well as cell and gene therapies, continue to provide ample manufacturing opportunities for contract manufacturing organizations (CMOs), says GlobalData.

According to the report from the data and analytics provider, New Drug Approvals and Their Contract Manufacture – 2022 Edition, over the last two years the FDA has awarded numerous EUAs to COVID-19 products, including Pfizer’s (Nasdaq: PFE) Comirnaty vaccine.

"Only a small amount of pharma companies will possess the manufacturing capabilities to produce cell therapies, and many outsource their products’ manufacture to a third party"Additionally, GlobalData’s analysis of the FDA’s drug approvals over the last decade found that 2021 was a record year for cell and gene therapy approvals.